durvalumab + tremelimumab

**Durvalumab + tremelimumab** is a dual immune-checkpoint-inhibitor regimen comprising durvalumab, a PD-L1-blocking human monoclonal antibody, and tremelimumab, a CTLA-4-blocking human monoclonal antibody. The agents act at complementary stages of antitumor immunity: tremelimumab promotes T-cell priming and activation through CTLA-4 blockade, while durvalumab prevents PD-L1-mediated suppression of activated T cells. AstraZeneca markets the individual components as Imfinzi and Imjudo; the regimen is not a single fixed-dose coformulated product. In the United States, the combination is approved for unresectable hepatocellular carcinoma, commonly using the STRIDE schedule of one priming dose of tremelimumab with durvalumab followed by durvalumab maintenance. Tremelimumab plus durvalumab is also approved when administered with platinum-based chemotherapy for metastatic non-small cell lung cancer without sensitizing EGFR mutations or ALK genomic tumor aberrations. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-unresectable-hepatocellular-carcinoma))

Brand names

ImjudoImfinzi

Other names

STRIDE